Many Patients Have Discontinuation Symptoms After Stopping Antidepressants
2024-06-06
临床结果临床研究
THURSDAY, June 6, 2024 -- A considerable proportion of patients have discontinuation symptoms (e.g., dizziness, headache, nausea, insomnia, and irritability) after discontinuing antidepressants, according to a review published online June 5 in The Lancet Psychiatry.
Jonathan Henssler, M.D., from the University of Cologne in Germany, and colleagues conducted a systematic review to examine the incidence of antidepressant discontinuation symptoms in patients discontinuing both antidepressants and placebo. Studies investigated cessation or tapering of an established antidepressant drug or placebo among patients with mental, behavioral, or neurodevelopmental disorders. Data were included from 79 studies with 21,002 patients: 16,532 patients discontinued from an antidepressant and 4,470 discontinued from placebo.
The researchers found that the incidence of at least one antidepressant discontinuation symptom was 0.31 and 0.17 in 62 study groups after discontinuation of an antidepressant and 22 study groups after discontinuation of placebo, respectively. The summary difference in incidence was 0.08 between antidepressant and placebo groups of included randomized controlled trials. The incidence of severe antidepressant discontinuation symptoms was 0.028 and 0.006 after discontinuation of an antidepressant and placebo, respectively. Higher frequencies of discontinuation symptoms were seen in association with desvenlafaxine, venlafaxine, imipramine, and escitalopram, while higher severity of symptoms was seen in association with imipramine, paroxetine, and either desvenlafaxine or venlafaxine. Substantial heterogeneity was seen for the results.
"Evidence that about one in 35 patients suffers from severe antidepressant discontinuation symptoms must be considered preliminary at present, but caution towards severe antidepressant discontinuation symptoms seems to be warranted when discontinuing imipramine, paroxetine, or desvenlafaxine and venlafaxine," the authors write.
Abstract/Full Text
Editorial (subscription or payment may be required)
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-药物
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。